01 August 2022

Completion of Loan Agreement and Partial Conversion

Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialization of Accrufer®/Feraccru® (ferric maltol), a novel, oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad indication, announces that following the Company’s general meeting held on 27 July 2022, the Company has concluded the formal loan documentation (the “Shareholder Loan Agreement”) in relation to the US$10 million loan (the “Shareholder Loan”) agreed between the Company and AOP Health International Management (“AOP”), an existing shareholder of the Company, as first announced by the Company on 30 June 2022, with further details set out in the circular sent to Shield’s shareholders on 8 July 2022.

For full details, click here.

Back to News